Cover Image

New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study

Xingyuan Gao,1,2 Man Yu,3 Yuyang Sun,3 Tiansi Zhang,1 Xin Li,1,3,4 Lingli Zhang,5 Changqing Wang1 1School of Health Policy and Management, Nanjing Medical University, Nanjing, People's Republic of China; 2Simcere Zaiming Pharmaceutical Co., Ltd., Nanjing, People's Republic of China; 3Schoo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gao X (Author), Yu M (Author), Sun Y (Author), Zhang T (Author), Li X (Author), Zhang L (Author), Wang C (Author)
Format:	Book
Published:	Dove Medical Press, 2024-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis
by: Lingli Zhang, et al.
Published: (2024)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
by: Hong Zhu, et al.
Published: (2022)

The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis
by: Yi Ding, et al.
Published: (2022)

Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis
by: Cui Li, et al.
Published: (2024)

The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis
by: Xuejing Rong, et al.
Published: (2020)

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis
by: Cong Huang, et al.
Published: (2022)

The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis
by: Zhaohui Qin, et al.
Published: (2024)

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
by: Cong Huang, et al.
Published: (2022)

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
by: Xia Mingge MPH, et al.
Published: (2023)

Impact of the Low-Price Medicine Policy on Medicine Supply in China: An Interrupted Time-Series Analysis
by: Mingyue Zhao, et al.
Published: (2021)

Effects of transparent online open procurement on prices, volumes, and costs of medicines: an interrupted time series study in Ningxia, China
by: Jingying Gao, et al.
Published: (2024)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
by: Di Wu, et al.
Published: (2022)

The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data
by: Bao-Xin Li, et al.
Published: (2024)

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
by: Ni Wang, et al.
Published: (2021)

Short- and long-term impacts of the National Essential Medicines Policy on drug availability, price, and usage in a deprived rural county in southwestern China: an interrupted time series analysis across 8 years
by: Xuechen Xiong, et al.
Published: (2024)

Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
by: Ashley Jaksa, et al.
Published: (2023)

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series
by: Hongfei Long, et al.
Published: (2022)

Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis
by: Yanyan Liu, et al.
Published: (2022)

Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study
by: Haishaerjiang Wushouer, et al.
Published: (2022)

The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
by: Hong D, et al.
Published: (2023)

The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis
by: Shuchen Hu, et al.
Published: (2019)

Impacts of the Zero-Markup Drug Policy on Hospitalization Expenses of Patients with Stroke in Western China: An Interrupted Time Series Analysis
by: Wu Y, et al.
Published: (2024)

Negotiating Medical Insurance Drug Prices: The Role in Reducing Costs of Orphan Drugs for Rare Diseases
by: Jinmiao Lu, et al.
Published: (2023)

Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin
by: Boya Zhao, et al.
Published: (2023)

Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available
by: F. V. Gorkavenko, et al.
Published: (2019)

Price variation among different brands of anticancer medicines available in hospital pharmacies of Nepal
by: Sunil Shrestha, et al.
Published: (2020)

Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients
by: Lili Shang, et al.
Published: (2024)

Time trends and regional variations in prices of anticancer medicines in China
by: Jinwei Zhang, et al.
Published: (2024)

Impact of China's zero mark-up drug policy on drug cost of NCDs' outpatients: an interrupted time series analysis
by: Jielin Du, et al.
Published: (2021)

The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis
by: Xiao Wang, et al.
Published: (2023)

Price increase negotiations to address drug shortages in South Korea's national health insurance
by: Seung Rae Yu, et al.
Published: (2023)

Impact of minimum unit pricing on alcohol purchases in Scotland and Wales: controlled interrupted time series analyses
by: Peter Anderson, ProfMD, et al.
Published: (2021)

The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis
by: Ruilin Wang, et al.
Published: (2023)

Impact of COVID-19 pandemic on food availability and affordability: an interrupted time series analysis in Ghana
by: Yoshito Kawakatsu, et al.
Published: (2024)

Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada
by: Rawson NSB, et al.
Published: (2024)

Price, availability and affordability of medicines
by: Brenda S. Mhlanga, et al.
Published: (2014)

Effect of the COVID-19 pandemic on utilization of essential health services in Iran evidence from an interrupted time series analysis
by: Mohammad Ranjbar, et al.
Published: (2024)

Effects of medical consortium policy on health services: an interrupted time-series analysis in Sanming, China
by: Xinmei Yang, et al.
Published: (2024)

The Impact of Prescribing Monitoring Policy on Drug Use and Expenditures in China: A Multi-center Interrupted Time Series Study
by: Xiaoyan Nie, et al.
Published: (2023)

A new entity for the negotiation of public procurement prices for patented medicines in Mexico
by: Octavio Gómez-Dantés, et al.
Published: (2012)